| 產品名稱 |
Human adenovirus 36 |
| 商品貨號 |
B177832 |
| Classification |
Adenoviridae, Mastadenovirus, Human adenovirus D |
| Agent |
Human adenovirus 36 |
| Strain |
275 |
| Applications |
Respiratory research |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen |
| Storage Conditions |
-70°C or colder |
| Comments |
Prepared from ATCC® VR-913™ following treatment to remove mycoplasma contamination.
No serological cross-reaction with other human adenoviruses. Hemagglutinin active for rat and human erythrocytes. |
| Effect on Host |
CPE, typical adenovirus rounding beginning in clusters |
| Recommended Host |
A549 (ATCC® CCL-185™)
|
| Growth Conditions |
Recommendations for Infection: For best results, plate cells 24-48 hours in advance. Infect at about 80% confluence using a multiplicity of infection (MOI) of 0.1 to 1.0. Incubate at 37°C for 3-7 days, until CPE are well advanced in 100% of the culture. A 5% CO2 in air atmosphere is recommended. |
| Name of Depositor |
R. Wigand, ATCC |
| Source |
Feces from human diabetic; derived from ATCC® VR-913™ following treatment to remove mycoplasma contamination. |
| References |
Wigand R, et al. New human adenovirus (candidate adenovirus 36), a novel member of subgroup D. Arch. Virol. 64: 225-233, 1980. PubMed: 7406681
|
